location： Home > Products > Signaling Pathways > Neuronal Signaling > AChR Receptor

Nitenpyram

Price：

Market Price：

This product is for research use only, not for human use. We do not sell to patients.

Number： - + Pieces（InventoryPieces）

InvivoChem Cat #: V1166

CAS #: 150824-47-8Purity ≥98%

Description: Nitenpyram (trade names Capstar, Bestguard), an insect neurotoxin of the neonicotinoid class, is a fast and long-acting, and orally bioavailable nicotinic acetylcholine receptor (AchR) agonist with neural signaling-blocking activity. It has been widely used as a veterinary medication to treat adult flea infestations, also used to treat parasites of livestock and pets.

References: J Agric Food Chem. 2016 Dec 14;64(49):9276-9285.

Customer Validation

Top Publications Citing Invivochem Products

详情页公告 Product Catalog 2022

Bulletin Board

详情页公告 Guide to Product Handling

Publications Citing InvivoChem Products

Physicochemical and Storage Information
Protocol
Quality Control Documentation
Related Biological Data
Customer Review

Molecular Weight (MW)	270.72
Formula	C11H15ClN4O2
CAS No.	150824-47-8
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 54 mg/mL (199.5 mM)
	Water: N/A
	Ethanol: 54 mg/mL (199.5 mM)
SMILES	O=[N+](/C=C(NC)/N(CC1=CC=C(Cl)N=C1)CC)[O-]
Synonyms	Nitenpyram; Capstar, Bestguard

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
- Mass
- Concentration
- Volume
- Molecular Weight *
- =
- ×
- ×
The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂
- Concentration _(start)
- ×
- Volume _(start)
- =
- Concentration _(final)
- ×
- Volume _(final)
- ×
- =
- ×
- C1
- V1
- C2
- V2

In Vitro	In vitro activity: Nitenpyram is a nicotinic acetylcholine receptor (AchR) agonist, used as veterinary medicine to treat parasites of livestock and pets. Nitenpyram is a new type of neonicotinoid insecticide with 2,2-bis(amino)nitroethene as the base structure, which has been developed by Takeda Pharmaceutical Company Limited.It is remarkably effective against pests of order Hemiptera, such as planthoppers, leafhoppers and aphids, and characterized by fast action, long lasting and systemic properties as well as safety for plants.
In Vivo	Nitenpyram is administered orally (1 mg/kg) for the short-term control of fleas in dogs and cats. Fleas start to fall from the animals 30 minutes post-administration and one dose can protect animals for 1-2 days.Since Nitenpyram is highly lipophilic, it is administered orally after the meal in order to induce bile flow to help dissolve the chemical, thereby increasing GI absorption of the drug. It is rapidly and completely absorbed from the GI tract in less than 90 minutes and is completely excreted in urine within 48 hours after oral administration to dogs and cats. Nitenpyram undergoes hydroxylation, followed by conjugation in the liver. The conjugates of Nitenpyram are excreted in the urine and Nitenpyram is not accumulated in body tissues. The plasma half-life of Nitenpyram in dogs and cats are 3 and 8 hours, respectively. It is likely that animals with liver and/or kidney problems may have longer plasma half-life of Nitenpyram
Animal model	Dogs and cats
Formulation & Dosage	1 mg/kg; oral
References	[1]. Vo DT, et al. Insect nicotinic acetylcholine receptor agonists as flea adulticides in small animals. J Vet Pharmacol Ther. 2010 Aug;33(4):315-22. [2]. Rust MK, et al. Efficacy and longevity of nitenpyram against adult cat fleas (Siphonaptera: Pulicidae). J Med Entomol. 2003 Sep;40(5):678-81.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Purity ≥98%
COA
MSDS
NMR

Home Prev Next Last page / pices

发评论

Your information is safe with us. * Required Fields.

Product name

Cat

Applicant name

Email address

Phone number

Organization name

Country

Requested quantity

Remarks